tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NUVL Stock Latest News

Nuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trial
The FlyNuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trial
5d ago
NUVL
Nuvalent resumed with a Buy at Stifel
PremiumThe Fly
Nuvalent resumed with a Buy at Stifel
9d ago
NUVL
Cantor starts Nuvalent at Overweight, sees 60% potential upside
PremiumThe Fly
Cantor starts Nuvalent at Overweight, sees 60% potential upside
9d ago
NUVL
Nuvalent initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Nuvalent initiated with an Overweight at Cantor Fitzgerald
9d ago
NUVL
Nuvalent’s Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potential
PremiumRatings
Nuvalent’s Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potential
12d ago
NUVL
Nuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
PremiumRatingsNuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
19d ago
NUVL
Nuvalent Completes New Drug Application Submission
Premium
Company Announcements
Nuvalent Completes New Drug Application Submission
1M ago
8K
NUVL
Nuvalent presents data from ARROS-1 trial of zidesamtinib
Premium
The Fly
Nuvalent presents data from ARROS-1 trial of zidesamtinib
2M ago
NUVL
Nuvalent’s Promising Oncology Pipeline Drives Buy Rating with $111 Price Target
PremiumRatings
Nuvalent’s Promising Oncology Pipeline Drives Buy Rating with $111 Price Target
2M ago
NUVL
Nuvalent assumed with a Buy at Guggenheim
PremiumThe Fly
Nuvalent assumed with a Buy at Guggenheim
2M ago
NUVL
Nuvalent assumed with a Buy at Guggenheim
PremiumThe Fly
Nuvalent assumed with a Buy at Guggenheim
2M ago
NUVL
Nuvalent initiated with an Outperform at Raymond James
PremiumThe Fly
Nuvalent initiated with an Outperform at Raymond James
2M ago
NUVL
Nuvalent initiated with an Overweight at Piper Sandler
PremiumThe FlyNuvalent initiated with an Overweight at Piper Sandler
2M ago
NUVL
Nuvalent Reports Q2 2025 Financials and Pipeline Progress
Premium
Company Announcements
Nuvalent Reports Q2 2025 Financials and Pipeline Progress
3M ago
NUVL
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
Premium
Ratings
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
3M ago
NUVL
Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating
PremiumRatings
Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating
3M ago
NUVL
Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
PremiumThe Fly
Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
3M ago
NUVL
Nuvalent’s Accelerated ALKAZAR Trial Progress and Strong Financials Justify Buy Rating
PremiumRatings
Nuvalent’s Accelerated ALKAZAR Trial Progress and Strong Financials Justify Buy Rating
3M ago
NUVL
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial
PremiumCompany Announcements
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial
3M ago
8K
NUVL
Nuvalent doses first patient in Alkazar trial
PremiumThe FlyNuvalent doses first patient in Alkazar trial
3M ago
NUVL
Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results
Premium
Ratings
Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results
4M ago
NUVL
Nuvalent assigned Buy rating, $105 price target at Goldman Sachs
Premium
The Fly
Nuvalent assigned Buy rating, $105 price target at Goldman Sachs
4M ago
NUVL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >